

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
Date of first issue: 22.11.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Pancrelipase Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
Shotton Lane
NE23 3JU Cramlington NU - Great Britain

Telephone : 44 1 670 59 30 00

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Respiratory sensitisation, Category 1	H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements : **Prevention:**
P264 Wash skin thoroughly after handling.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes skin irritation.
Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : High volume water jet

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Do not use a solid water stream as it may scatter and spread fire.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

Sulphur oxides
Metal oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
-

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Technical measures : Static electricity may accumulate and ignite suspended dust
-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
Date of first issue: 22.11.2019

- causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
Advice on safe handling : Do not get on skin or clothing.
Avoid breathing dust, fume, gas, mist, vapours or spray.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.
Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

- Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Pancrelipase	53608-75-6	TWA	OEB 3 ($\geq 10 < 100$ $\mu\text{g}/\text{m}^3$)	Internal
Starch	9005-25-8	TWA (inhalable dust)	10 mg/m^3	GB EH40

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
 Date of first issue: 22.11.2019

	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.</p>			
		TWA (Respirable dust)	4 mg/m ³	GB EH40
	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.</p>			
Calcium carbonate	471-34-1	TWA (inhalable dust)	10 mg/m ³	GB EH40
	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respira-</p>			

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
Date of first issue: 22.11.2019

	<p>ble, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.</p>			
	<table border="1"><tr><td>TWA (Respirable dust)</td><td>4 mg/m³</td><td>GB EH40</td></tr></table>	TWA (Respirable dust)	4 mg/m ³	GB EH40
TWA (Respirable dust)	4 mg/m ³	GB EH40		
	<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m⁻³ 8-hour TWA of inhalable dust or 4 mg.m⁻³ 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with., Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.</p>			

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Calcium carbonate	Workers	Inhalation	Long-term systemic effects	6.36 mg/m ³
	Consumers	Ingestion	Acute systemic effects	6.1 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic	1.06 mg/m ³

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
Date of first issue: 22.11.2019

			effects	
	Consumers	Ingestion	Long-term systemic effects	6.1 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Calcium carbonate	Sewage treatment plant	100 mg/l

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to BS EN 143
- Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- Appearance : solid
- Colour : No data available
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form combustible dust concentrations in air.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

10.3 Possibility of hazardous reactions

Hazardous reactions : May form combustible dust concentrations in air.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Pancrelipase:

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg

Skin corrosion/irritation

Causes skin irritation.

Components:

Pancrelipase:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Pancrelipase:

Result : Irritation to eyes, reversing within 21 days
Remarks : Based on data from similar materials

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version 1.3 Revision Date: 09.04.2021 SDS Number: 5325634-00004 Date of last issue: 10.10.2020
Date of first issue: 22.11.2019

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Pancrelipase:

Exposure routes : Inhalation
Species : Humans
Result : positive
Remarks : Based on data from similar materials

Assessment : May cause sensitisation by inhalation.

Germ cell mutagenicity

Not classified based on available information.

Components:

Pancrelipase:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Pancrelipase:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Pancrelipase:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks
Method : OECD Test Guideline 408
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

SECTION 12: Ecological information

12.1 Toxicity

Components:

Pancrelipase:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 1 - 10 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): > 1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

Pancrelipase:

Biodegradability : Result: Readily biodegradable.

12.3 Bioaccumulative potential

Components:

Pancrelipase:

Partition coefficient: n-octanol/water : log Pow: < 4

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Full text of other abbreviations

Eye Irrit. : Eye irritation
Resp. Sens. : Respiratory sensitisation
Skin Irrit. : Skin irritation
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet;

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



Pancrelipase Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.3	09.04.2021	5325634-00004	Date of first issue: 22.11.2019

SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Resp. Sens. 1	H334

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN